logo
Australian uranium explorers are shaping up for a tectonic shift in sentiment

Australian uranium explorers are shaping up for a tectonic shift in sentiment

News.com.aua day ago
Despite boasting the world's largest resources Australia's policies around uranium mining are uneven
Queensland could be ready to soften its stance if the right project comes along
Greenvale Energy is preparing to explore the high-grade Oasis project near Townsville, as it aims to become the state's yellowcake flag bearer
Australia's uranium potential is often a topic of contention, with some states having moratoriums around mining yellow cake.
That's despite a shift in sentiment across the globe, with other countries across the OECD pivoting towards nuclear energy in a bid to shore up both net zero targets and energy security.
The United States has been doing much of the heavy lifting there. President Donald Trump has big dreams to quadruple nuclear energy capacity in the US to 400GW by 2050.
It wants domestic, or at least friendly, sources of supply, as the US competes with Russia and China to claim its status as an "energy superpower".
That macro demand picture and relatively stable prices of US$70/lb for spot and US$80/lb for term contracts, has exploration activity rising in Australia even without a nuclear industry of our own.
Greenvale Energy (ASX:GRV) is one company gearing up to start drilling at its newly acquired Oasis project in Queensland, and CEO Alex Cheeseman told Stockhead that uranium mining the state might not always be in the doghouse.
'The understanding we have from engagement with government is that the current Queensland government will look to and consider overturning the uranium mining ban if and when a project of merit is put forward,' he said.
'I don't want to anchor the company's hopes on the whims of government, so we spread our risk by having projects in other states and territories as well.
'But Queensland is a mining state, and with the demise of coal mining they're going to need to start looking at other commodities and a sensible approach to uranium mining I think is definitely on the cards.'
It also comes down to a marked change in sentiment globally towards nuclear energy, especially if we want to hit net zero targets.
'Australia has been mining and exporting uranium for 50-60 years. We don't have a nuclear industry in Australia but it feeds into a global market,' Cheeseman said.
'The US, China and even Europe are doubling down massively on nuclear energy for future energy requirements to achieve net zero, and for zero carbon emissions energy supply into the future.
'And Australia has always been involved in digging things out of the ground, concentrating them and then sending them off elsewhere to feed into a global supply chain – whether it be iron ore or lithium. I think uranium is part of that.
'I think there's a misconception that if you're mining uranium you need to have a nuclear industry in Australia, but we don't have battery manufacturing in Australia (and) make a lot of money selling lithium off to China, for example.'
Value proposition
As for Oasis, if it eventually gets into production, GRV sees similarities to the monstrous Rossing uranium mine in Namibia, once owned by Rio Tinto (ASX:RIO) and now the longest running uranium mine in the world.
Originally found in Australia's original uranium exploration rush in the 1970s, Oasis hosts historical intercepts up to 1m at 0.72% U3O8 (15.8 lbs/t).
Cheeseman said the main appeal was picking up a project that already had some known mineralisation, 'and the potential for a defining a resource that warrants a future mine.'
A recent $1.8m cap raising for the company, which features Pilbara Minerals (ASX:PLS) founder Neil Biddle as its chair, will support Greenvale's plans to drill the project and will also drive the next phase of exploration across its Elkedra and Douglas River Uranium Projects in the Northern Territory.
'The value proposition we have is that we've been investing in securing uranium projects and starting early-stage work for a good 9-12 months so we're really an early mover,' Cheeseman said.
'We're not waiting until the market gets super-hot and then piling into it like most juniors do.
'We think there's a long-term structural deficit of uranium supply, that's putting upwards pressure on pricing, so we've decided to invest early in early stage exploration and then we'll advance projects to make discoveries, define resources and be ahead of the pack as the price really starts to gain traction.
'We see something coming and we want to be ahead of the curve.'
Who else has an Aussie uranium project?
Boss Energy (ASX:BOE)
The most notable player in Australia is Boss with its Honeymoon mine in South Australia, where production kicked off at the start of 2024 after it was closed by previous owner UraniumOne back in 2013.
Honeymoon is now one of three active uranium producers in Australia alongside BHP's (ASX:BHP) Olympic Dam (where it is a by-product of copper and gold mining) and the Beverley uranium mine.
Boss' first full year of operations was a good one, delivering 872,607lb of drummed U3O8. Second half costs clocked in at $35/lb (US$23/lb) on a C1 basis.
But the long term outlook for the mine was significantly written down. While a ramp up to 1.6Mlb at C1 costs of $41-45/kb (US$27-29/lb) and AISC of $64-70/lb (US$41-45/lb) is expected in FY26, the company warned that it may be unable to hit the previously assumed 2.1Mlbpa nameplate capacity of the mine.
Boss shares have tumbled from $4.67 on June 30 to $1.77, with MD Duncan Craib already announcing before the guidance update that he would step aside for former IGO executive and company COO Matt Dusci.
Deep Yellow (ASX:DYL)
The company's merger with Vimy Resources included the 7.1Mlbpa Mulga Rock project in WA, which could start production as soon as 2028.
Rising uranium prices have sent Deep Yellow's shares some 32% higher since it announced a merger with Vimy Resources.
The project was the only future mine approved by the pro-uranium Barnett Liberal-National Government in WA before the entry of the anti-uranium McGowan Labor Government in 2017 which also beat a five-year substantial commencement deadline set out in its environmental approval.
A DFS on the ~15-year Mulga Rock is currently underway.
Deep Yellow also owns the more advanced Tumas project in Namibia.
Core Energy Minerals (ASX:CR3)
Last month CR3 kicked off maiden drilling at its Cummins uranium project in South Australia targeting 'roll front' style mineralisation.
Historical drilling data – validated by French state-owned uranium exploration company Areva in 2009 – points to several broad, shallow zones of radioactive mineral concentrations over an area of more than 10km.
CR3 has since interpreted several areas to host roll front mineralisation prospective for uranium, representing high-priority areas for the maiden drilling campaign.
The company also owns the Brooker project, which sits directly to the northeast of Cummins along the western margin of the Port Lincoln Uplands in an area with several uraniferous granite source rocks and uranium occurrences.
Koba Resources (ASX:KOB)
KOB has notched up three new high-grade uranium finds at its Yarramba project in the past 12 months, right next to producing operations in South Australia.
The latest find, the Everest prospect, is immediately north of Boss' 10.7Mlb Jasons Deposit and the Honeymoon uranium mine.
That addition takes the count to three high-grade discoveries for KOB, all grading above 1000ppm, joining Berber (1.6m at 1026ppm) and Chivas (0.5m at 1028ppm).
With heritage approvals now in hand, the company is set to begin infill and extensional drilling in September.
Heavy Rare Earths (ASX:HRE)
Since pivoting towards uranium last year with the acquisition of three uranium projects in South Australia near established mining operators, Heavy Rare Earths has been positioning for potential M&A interest if a major find emerges.
Until that point, the company was focused on its Cowalinya rare earths project near Esperance, WA, a deposit comparable in style to the massive ion-adsorption clay types found in southern China and Myanmar, where most of the world's heavy rare earths are sourced.
But, with an eye on the long-term value of critical minerals, the company viewed the opportunity to acquire three assets from Havilah Resources (ASX:HAV) – in one of the world's premier uranium producing jurisdictions – as highly compelling.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health Check: Pro Medicus banks the profits as customers go the ‘full stack'
Health Check: Pro Medicus banks the profits as customers go the ‘full stack'

News.com.au

time21 minutes ago

  • News.com.au

Health Check: Pro Medicus banks the profits as customers go the ‘full stack'

Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run The $32 billion market cap ProMedicus (ASX:PME) has drawn the chapter on what co-founder and CEO Dr Sam Hupert dubs 'the most successful year in the company's history by any measure'. The US-focused radiology imaging house today posted revenue of $213 million for the full year to June 30 2025, up 32%. Net earnings surged 39%, to $115 million. While the numbers were pretty much as expected, the shares surged up to 7% on the prospect of further revenue gains from newly-written contracts. The company is also expanding into areas such as cardiology and pathology – the latter of which could be two-thirds the size of the radiology market. "But it's early days." Hupert describes a 'record year of new contract wins, contract renewals and sales of additional modules'. Revenue rose in the three key jurisdictions of the US, Germany and Australia, but North America led the way with a 36% increase. The company derives about 90% of its revenue from the US. During the year, Pro Medicus won $520 million of new contracts. Yep, that's a record. These included a monster $330 million deal with Trinity Health, one of the biggest not-for-profit networks in the US. The company also signed two key renewals, totalling $130 million. Hupert says more customers are going the 'full stack', which means they are availing of the company's image viewing, archiving and workflow tools. Only the beginning? He adds that many of the recently signed contacts will come on stream 'in the next year and beyond', which means 98% of this revenue is yet to be recognised. He cites forward contracted revenue for the next five years at $948 million, up from $624 million a year ago. Despite the growth, Pro Medicus still accounts for only 10% of the US total addressable market. The company still trades on an extravagant price-earnings multiple, which implies that this 10% will become a much bigger number in the near future. 'We don't have a fixed target in mind, our aim is to get as big a percentage market share as possible,' Hupert says. 'Importantly, we do not see any technical or capacity-related reason why we will not continue to increase our market share materially from here.' Hupert says the company's recent $10 million loan facility to lung imager 4D Medical (ASX:4DX) related to the companies AI capabilities. There's the prospect of adding one or morr 4D products to the Pro Medicus stable. "But I wouldn't read more into it than that." Broker RBC says while the result was broadly in line with consensus, the company pleased with its free cash flow generation and upbeat outlook on contracts. RBC has a 'hold' rating on the stock with a 'price target' of $350. Starpharma shares take a run Starpharma (ASX:SPL) CEO Cheryl Maley's prezzo to Bioshares annual summit in Hobart last week appears to have been enough to spark a 50% share run. The contents weren't new, but Maley did outline how management had tweaked the company's strategy over the last year. Maley started in January 2024. Otherwise, Starpharma's June quarterly report showed customer receipts of $2 million, 51% higher than the March quarter. Net cash outflows were $2 million. Starpharma's reason for being is its dendrimer enhanced product (DEP) platform, which has produced the commercialised bacterial vaginosis treatment Vivagel and the germ-busting nasal spray Viraleze. Before you ask, dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss). The company has oncology programs that combine the dendrimer with three existing drugs. They are irinotecan (colorectal cancer), cabazitaxel (prostate cancer and others). Management is attempting to outlicense these assets. Maley says despite considerable interest 'the licensing process has taken longer than anticipated.' She attributes this to factors including "the evolving oncology landscape shifting towards targeted treatment options and the current geo-political environment, which has impacted the biotechnology industry at large". Starpharma ended the quarter with cash of $15.5 million – enough funding for close to two years – with an expected $3.5 million R&D tax rebate yet to come. Starpharma shares today had a well-earned rest, falling around 10%. Rhythm limbers up for raising Rhythm Biosciences (ASX:RHY) shares are on trading halt pending a capital raising announcement, on or before next Monday. It's not a bad time for the company to tap the market, given its shares have gained 75% over the last month. Rhythm is developing Colostat, a blood-based cancer assay which could replace the commonly used 'poo' tests. The company also owns Genetype, a genetic risk assessment testing platform combining clinical, family history and genetic data. Rhythm bought this asset from the administrators of Genetic Technologies. Tetratherix gets a grant Of course, the best form of funding is the free variety and the recently listed Tetratherix (ASX:TTX) has come up trumps in this regard. The wound-care house has been awarded $3.3 million of non-dilutive funding, under the federal Industry Growth Program grant. Tetratherix is commercialising products based on its polymer biomaterials, which offer claimed benefits such as increased flexibility and bioresorbability. The grant will partly fund a $7.4 million project to take its Tetramatrix platform global, including expanding its production facility near Sydney Airport. The funding spans the current financial year and 2026-27. Tetratherix shares have gained a sprightly 40% since listing on June 30, the only local life sciences IPOs year to date. But if you think that's a drought, there been no US biotech IPO for six months. The last one was diseases specialist Aardvark Therapeutics, which listed on the Nasdaq in mid-February.

Guy on Rocks: Pencils down on much anticipated iron ore scoping study
Guy on Rocks: Pencils down on much anticipated iron ore scoping study

News.com.au

time43 minutes ago

  • News.com.au

Guy on Rocks: Pencils down on much anticipated iron ore scoping study

Guy on Rocks' is a Stockhead series looking at the significant happenings of the resources market each week. Former geologist and experienced stockbroker Guy Le Page, director, and responsible executive at Perth-based financial services provider RM Corporate Finance, shares his high conviction views on the market and his 'hot stocks to watch'. This week on Guy on Rocks, host Guy Le Page assesses the much-anticipated scoping study released by Cyclone Metals (ASX:CLE) on its Iron Bear iron ore project in Newfoundland, Canada. With a resource estimate of 16.66Bt at 29.3% iron, standout figures include a post-tax US$9.79 billion NPV and a mine life of 18 years based on just 9% of the total mineral resource alone. Perhaps most importantly, CLE has the financial backing of Brazilian iron ore major Vale. Tune in to hear more. While Cyclone Metals did not collaborate on this video, it is a Stockhead advertiser at the time of publishing. The views, information, or opinions expressed in this video are solely those of the author and do not represent the views of Stockhead.

‘We don't want you here': Zohran Mamdani ambushed by Staten Island protesters at anti-Trump rally
‘We don't want you here': Zohran Mamdani ambushed by Staten Island protesters at anti-Trump rally

Sky News AU

timean hour ago

  • Sky News AU

‘We don't want you here': Zohran Mamdani ambushed by Staten Island protesters at anti-Trump rally

Protesters in Staten Island have slammed Democrat New York City mayoral candidate Zohran Mamdani. Mamdani's visit to Staten Island sees him participate in his third anti-Trump event of the week at a local Mediterranean restaurant. The mayoral candidate was flamed by a Trump supporter yelling, "We don't want you here on Staten Island." During his speech, Mamdani vowed to protect New Yorkers from Trump's crackdown on illegal immigration if elected. "I will not let it dissuade me from continuing to come to Staten Island, from continuing to speak to New Yorkers, no matter where they live, no matter what politics they have," Mamdani said. According to recent polling, Mamdani is 19 points ahead in the five-person race for mayor. Another demonstrator questioned why Mamdani came to Staten Island, calling it "Trump country".

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store